Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma

Medicenna Therapeutics, Corp. announced NEO-CYT, a randomized, investigator‑initiated neoadjuvant trial testing MDNA11, a long‑acting, “beta‑enhanced not‑alpha” IL‑2 Superkine, in combination with nivolumab with or without ipilimumab for patients with high‑risk, surgically resectable Stage III cutaneous melanoma.